Business Context and Reporting Period
Company: LifeVantage Corp.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2011
Business Overview: LifeVantage is a science-based company focused on oxidative stress solutions, primarily marketing the dietary supplement Protandim® and the anti-aging skin care product LifeVantage TrueScience®. The company utilizes a network marketing sales channel involving independent distributors in the U.S., Japan, Mexico, and Canada. In March 2011, Douglas C. Robinson was appointed President and CEO, succeeding David W. Brown.
Key Financial Metrics
| Metric | Fiscal Year 2011 | Fiscal Year 2010 |
|---|---|---|
| Net Sales | $38,919,223 | $11,478,460 |
| Gross Profit | $33,001,829 | $9,572,468 |
| Gross Margin | 84.8% | 83.4% |
| Operating Income | $3,702,204 | $(7,321,952) |
| Net Loss | $(50,791,750) | $(11,048,328) |
| Cash and Cash Equivalents | $6,370,974 | $1,637,676 |
| Working Capital | $(3,105,045) | $(2,103,899) |
| Net Cash Provided by Operating Activities | $4,680,925 | $(4,499,483) |
Note: The significant Net Loss in 2011 is primarily driven by a non-cash charge of $48.5 million related to the change in fair value of derivative liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 240% ($27.4 million) year-over-year, driven by significant expansion in the network marketing channel, particularly in the U.S. and Japan.
- Operating Profitability: The company achieved its first operating profit since fiscal 2005, turning a $7.3 million operating loss in 2010 into a $3.7 million operating profit in 2011. This was achieved despite a 73% increase in operating expenses, which was largely due to higher distributor commissions.
- Derivative Liability Impact: While operations improved, the bottom line was severely impacted by a $48.5 million expense from the change in fair value of derivative liabilities (warrants and embedded conversion features), compared to a $3.1 million gain in the prior year. This was caused by fluctuations in the company's stock price.
- Liquidity: Cash and cash equivalents increased by $4.7 million to $6.4 million, supported by positive cash flow from operations.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management expects sales growth to continue in fiscal 2012 as the company adds new customers and expands into international markets. Gross margins are expected to remain in the 83-85% range. The company believes it has sufficient cash on hand to fund operations through at least June 30, 2012.
Unusual Items
- Derivative Accounting: The massive net loss is non-cash in nature, resulting from the mark-to-market accounting of derivative liabilities associated with convertible debentures and warrants issued in prior financing rounds.
- Stock Repurchase Program: In September 2011 (subsequent to period end), the Board approved a $5 million share repurchase program.
Risks and Contingencies
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, specifically regarding insufficient accounting personnel and inadequate oversight of accounting functions. Remediation is planned by June 2012.
- Single Product Dependence: Revenue is heavily dependent on the Protandim® product line.
- Regulatory Environment: The business is subject to strict FDA and FTC regulations regarding dietary supplements and network marketing practices. There is a risk of investigatory action by the FTC.
- Dilution: The company has significant outstanding warrants and options (approx. 36 million shares) that could materially dilute existing shareholders if exercised.
Investor Verification Checklist
- Derivative Liability Valuation: Verify the assumptions used (volatility, stock price) in the Black-Scholes model that resulted in the $48.5 million non-cash charge.
- Internal Control Remediation: Monitor progress on hiring accounting staff and implementing oversight to address the material weaknesses in financial reporting.
- Distributor Churn: Assess the sustainability of revenue growth by analyzing independent distributor retention rates and the ratio of active distributors to total recruits.
- Regulatory Status: Confirm there are no pending or new investigations by the FTC or FDA regarding product claims or network marketing compensation plans.
- Cash Burn vs. Operations: Reconcile the positive operating cash flow ($4.7M) against the negative working capital position to ensure liquidity is sufficient for the stated 12-month runway.